Passionate about patient care and making a difference | HemOnc, Plasma Cell Disorders Division | Levine Cancer Institute | tweets & views expressed are my own
“President Trump might like to believe that we can just build a wall around this country, but pandemics don’t respect walls.” — Fmr. US Ambassador to the United Nations Samantha Power
https://t.co/LQG2R0rofP
I know this is hard.
I wish I could say this will be over soon, but I can’t.
We must make decisions based on the science and the data.
Human lives are at stake.
Halting funding for the World Health Organization during a world health crisis is as dangerous as it sounds. Their work is slowing the spread of COVID-19 and if that work is stopped no other organization can replace them. The world needs @WHO now more than ever.
PSA on #COVID
1) Do not listen to advice from politicians and bankers on when it’s safe to stop social distancing. They have vested interests. Listen to real experts, and infection control professionals. #COVID@PSampathkumarMD @dan_diekema @CarlosdelRio7@dr_dmorgan@ASlavitt
I admit that I’ve never done the background research but this very topic has been coming to mind lately. I’m not a big “hugger” but there are those times when only a good hug will do. #ash17 reflections #lci @Carolinas https://t.co/4oQVs00Cgn
It takes a #TEAMM to care for our #myeloma patients. Multi-center, Phase3 study on abx ppx (Levofloxacin 500mg BID vs placebo x 12 wks). 1’endpoint-febrile episodes/death. n=997. Clinically significant p value (HR=O.66, p=0.002)favoring levo ppx #ash17#mmsm
bb2121 - impressive results 94% response rate. Median PFS not yet reached at ~9-10 months. MRD negative level depth of patients in 90% of evaluates patients. @MayoClinic was a key participant #ASH17#ASH17VR@mtmdphd@MyelomaTeacher@jmikhaelmd@Rfonsi1 https://t.co/BSJD4b2aFm
Our fearless leader getting ready for the next #ash17 oral session #LCI @Carolinas Plasma Cell Disorders Program Director, Dr. Saad Usmani. Join in Hall C1 for more #myeloma updates #mmsm@szusmani
Updates on #ASPIRE#mmsm@ASH_hematology @akeithstewart presents data once again confirming improved overall survival with KRd vs Rd, 48.3 vs 40.4 mo (HR 0.79, P=0.0045) when used >=1st relapse #myeloma@Amgen